Press releases
- Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
- Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
- Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
- Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
- Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
More ▼
Key statistics
As of last trade Atara Biotherapeutics Inc (AT2:DUS) traded at 0.3635, 0.00% above its 52-week low of 0.3635, set on Jun 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.3635 |
Low | 0.3635 |
Bid | -- |
Offer | -- |
Previous close | 9.09 |
Average volume | -- |
---|---|
Shares outstanding | 4.90m |
Free float | 4.46m |
P/E (TTM) | -- |
Market cap | 37.81m USD |
EPS (TTM) | -52.93 USD |
Data delayed at least 15 minutes, as of Jun 19 2024 08:10 BST.
More ▼